查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1370927

营养保健品 CDMO 市场 - 2018-2028 年全球产业规模、份额、趋势、机会与预测，按剂型、服务、公司规模、地区、竞争细分

Nutraceuticals CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Dosage Form, By Service, By Company Size, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球营养保健品CDMO 市场在2022 年达到340.9 亿美元的估值，预计将以7.87% 的复合年增长率实现令人印象深刻的增长，预计到2028 年将达到534.5 亿美元。营养保健品CDMO 代表合约开发和製造组织，指为营养保健品公司提供开发和製造服务的公司。营养保健品是结合食品和药物成分的产品，提供基本营养以外的健康益处。另一方面，CDMO 则透过协助其产品的开发、製造，有时甚至行销来满足製药、生物技术和营养保健品公司的需求。 CDMO 提供专业知识、设施和资源，在产品生命週期的各个阶段（从研发到製造和分销）为客户提供支援。

主要市场驱动因素

  • 1.营养保健品需求的成长推动市场成长：营养保健品需求的激增大大推动了全球保健品 CDMO 市场的扩张。随着消费者对营养保健品的兴趣持续上升，对创新和差异化产品的需求不断增加。营养保健品公司通常需要专业知识来开发和配製符合消费者偏好和健康要求的新产品。营养保健品 CDMO 提供研发能力，协助公司创造新颖的配方，在市场上提供更广泛的营养保健产品。对营养保健品的高需求需要扩大生产能力，而营养保健品 CDMO 拥有有效生产大量产品的基础设施和专业知识，以满足成熟和新兴保健品品牌的需求。
市场概况
预测期 2024-2028
2022 年市场规模 340.9亿美元
2028 年市场规模 534.5亿美元
2023-2028 年复合年增长率 7.87%
成长最快的细分市场 片剂和胶囊
最大的市场 北美洲
  • 2.慢性病盛行率的增加推动市场成长：慢性病发生率的上昇在推动全球营养药品 CDMO 市场方面发挥重要作用。心血管疾病、糖尿病、肥胖和神经退化性疾病等慢性疾病通常与生活方式因素和不良饮食选择有关。消费者越来越积极主动地关注自己的健康，寻求预防措施来降低慢性病的风险。营养保健品具有潜在的健康益处，被视为预防性医疗策略的一部分。营养药品 CDMO 在开发和製造这些产品以满足不断增长的需求方面发挥关键作用。营养保健品因其在管理慢性疾病方面的潜在治疗益处而日益得到认可，营养保健品 CDMO 与製药和营养保健品公司合作，开发针对特定慢性病的专门产品。
  • 3.研发进步推动市场成长：研发（R＆D）的进步大大促进了全球营养药品 CDMO 市场的成长。研发进步导致营养保健品的新颖成分、配方和输送系统的发现。营养药品 CDMO 与营养药品公司合作，将这些创新转化为可上市的产品。研发进步也使人们更深入了解各种营养素和生物活性化合物的健康益处和作用机制。营养保健品 CDMO 促进科学研究与产品开发的整合，使公司能够创建经过临床验证和证实的实证营养保健品。这些进步使人们能够更好地了解营养保健品可以解决的特定健康问题和状况，从而开发出有针对性的健康解决方案。此外，研发也根据遗传、生活方式和健康状况增强了对个人营养需求的了解，从而能够创造出个人化的营养解决方案。

主要市场挑战

  • 1.品质控制和保证：由于确保一致的产品品质和安全性的复杂性和关键性，品质控制和保证对全球营养药品 CDMO 市场构成了重大挑战。营养保健品须遵守监管标准，以确保其安全性、有效性和准确的标籤。遵守不同地区多样化且不断变化的法规可能非常复杂且耗时。营养药品 CDMO 必须跟上不断变化的法规并相应地调整其流程。确保不同批次的品质和效力一致具有挑战性，特别是对于含有多种活性成分的复杂配方。成分特性的变化，例如易受季节变化影响的天然成分，可能会使过程复杂化。营养药品 CDMO 必须仔细选择供应商并建立严格的品质标准，以尽量减少变异。
  • 2.成分采购和供应链中断：成分采购和供应链中断可能对全球营养药品 CDMO 市场带来重大挑战。成分供应商的可靠性和一致性可能会有所不同，从而影响营养保健品配方的基本成分的品质和可用性。许多营养保健品成分均源自天然来源，且可用性和品质可能会受到季节性变化的影响，从而影响产品配方的一致性。地缘政治因素、贸易限制和自然灾害可能会扰乱供应链并影响原料的供应。确保原材料的品质和真实性至关重要，需要严格的测试和验证流程。
  • 3.环境永续性：环境永续性对全球营养药品 CDMO 市场提出了重大挑战，因为该产业寻求平衡业务成长与负责任的环境实践。营养保健成分通常会产生生态影响，例如森林砍伐和栖息地破坏，并可能威胁当地的生态系统和生物多样性。该行业还产生废物，包括包装材料和副产品。透过永续采购实践、负责任的废弃物管理和环保包装替代品来减少对环境的影响至关重要。此外，製造过程中的能源消耗和温室气体排放必须透过节能技术和再生能源来解决。

主要市场趋势

  • 1.个人化营养的兴起：个人化营养是全球营养保健品 CDMO 市场的重要趋势，影响营养保健品的开发、配製和製造方式。这一趋势涉及根据个人独特的健康需求、基因组成、生活方式和偏好量身定制饮食和补充剂建议。营养药品 CDMO 在开发符合每个消费者俱体要求的定製配方方面发挥关键作用。这一趋势要求 CDMO 具备专业知识，能够创造出多样化且灵活的配方，并可根据个人因素进行调整。个人化营养依赖于全面的健康评估、生物标记分析和基因测试来确定个人的营养需求，CDMO 可以与测试实验室和医疗保健专业人员合作，将这些资料纳入配方过程。
  • 2.剂型主导：2022年，片剂和胶囊领域主导营养药品CDMO市场，预计将持续扩大。片剂和胶囊因其方便、易于食用和精确的剂量能力而成为流行的剂型。它们为封闭成分提供稳定性和保护，免受环境因素的影响并有助于延长保质期。预计 2023 年至 2030 年该细分市场将经历最高的年复合成长率(CAGR)。
  • 3.製造和包装服务：製造和包装服务在营养药品 CDMO 市场中至关重要。製造服务包括营养保健品的生产，而包装服务则涉及零售或分销的设计、标籤和包装。有效的包装对于产品差异化、消费者沟通和法规遵循至关重要。
  • 4.中型 CDMO：中型营养保健品 CDMO 敏捷且反应灵敏，提供个人化服务并建立强大的客户关係。他们通常专注于营养保健品产业，在配方、製造、监管合规性和市场趋势方面拥有深厚的专业知识。中型 CDMO 以创新和适应性而闻名，能够快速响应市场变化并推出

独特的营养保健品。

  • 5.北美主导地位：北美，特别是美国，由于成熟的市场、消费者对膳食补充剂的强烈接受度以及完善的监管框架，在全球营养保健品CDMO市场中处于领先地位。北美消费者对健康和保健的日益关注推动了对营养保健产品的需求，从而导致对 CDMO 服务的更大需求。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球保健品 CDMO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按剂型（片剂和胶囊、粉末、软胶囊、其他）
    • 按服务（产品配方和开发、製造和包装、研究与开发 (R&D)、法规合规性、其他）
    • 依公司规模（小型公司、中型公司、大型公司）
    • 按公司划分 (2022)
    • 按地区
  • 市场地图

第 6 章：北美营养药品 CDMO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依剂型分类
    • 按服务
    • 按公司规模
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲营养药品 CDMO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依剂型分类
    • 按服务
    • 按公司规模
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太营养保健品 CDMO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依剂型分类
    • 按服务
    • 按公司规模
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲营养药品 CDMO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依剂型分类
    • 按服务
    • 按公司规模
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲营养药品 CDMO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依剂型分类
    • 按服务
    • 按公司规模
    • 按国家/地区
  • MEA：国家分析
    • 南非营养保健品 CDMO
    • 沙乌地阿拉伯营养保健品 CDMO
    • 阿联酋营养保健品 CDMO

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • Catalent Inc.
    • Lonza Group AG
    • NUTRASCIENCE LABS Inc
    • Robinson Pharma, Inc.
    • Health Wright Products, Inc.
    • Innovations in Nutrition + Wellness
    • INPHARMA SpA
    • Aenova Group
    • NutraPakUSA
    • SFI Health Pty Ltd.

第 16 章：策略建议

简介目录
Product Code: 17092

The Global Nutraceuticals CDMO Market achieved a valuation of USD 34.09 Billion in 2022 and is poised for impressive growth at a projected CAGR of 7.87% and is expected to reach USD 53.45 Billion by 2028. Nutraceuticals CDMO, which stands for Contract Development and Manufacturing Organization, refers to companies that provide development and manufacturing services to nutraceutical firms. Nutraceuticals are products that combine food and pharmaceutical components, offering health benefits beyond basic nutrition. CDMOs, on the other hand, cater to pharmaceutical, biotechnology, and nutraceutical companies by assisting in the development, manufacturing, and occasionally even marketing of their products. CDMOs bring specialized expertise, facilities, and resources to support clients across various stages of the product lifecycle, from research and development to manufacturing and distribution.

Key Market Drivers

  • 1. Growing Demand for Nutraceutical Products Drives Market Growth: The surging demand for nutraceutical products significantly fuels the expansion of the Global Nutraceutical CDMO market. As consumer interest in nutraceuticals continues to rise, there's a heightened need for innovative and differentiated products. Nutraceutical companies often require specialized expertise to develop and formulate new products that align with consumer preferences and health requirements. Nutraceutical CDMOs offer research and development capabilities to assist companies in creating novel formulations, leading to a more extensive variety of nutraceutical products in the market. The high demand for nutraceutical products necessitates the scaling up of manufacturing capacities, and Nutraceutical CDMOs have the infrastructure and expertise to efficiently produce larger quantities of products, catering to both established and emerging nutraceutical brands.
Market Overview
Forecast Period2024-2028
Market Size 2022USD 34.09 Billion
Market Size 2028USD 53.45 Billion
CAGR 2023-20287.87%
Fastest Growing SegmentTablets & Capsules
Largest MarketNorth America
  • 2. Increasing Prevalence of Chronic Diseases Drives Market Growth: The rising incidence of chronic diseases plays a significant role in propelling the Global Nutraceutical CDMO market. Chronic diseases such as cardiovascular diseases, diabetes, obesity, and neurodegenerative disorders are often linked to lifestyle factors and poor dietary choices. Consumers are increasingly proactive about their health, seeking preventive measures to mitigate the risk of chronic diseases. Nutraceutical products, with their potential health benefits, are being viewed as part of preventive healthcare strategies. Nutraceutical CDMOs play a pivotal role in developing and manufacturing these products to meet the growing demand. Nutraceuticals are increasingly recognized for their potential therapeutic benefits in managing chronic diseases, and Nutraceutical CDMOs collaborate with pharmaceutical and nutraceutical companies to create specialized products targeting specific chronic conditions.
  • 3. Advancements in Research and Development Drive Market Growth: Progress in research and development (R&D) significantly contributes to the growth of the Global Nutraceutical CDMO market. R&D advancements lead to the discovery of novel ingredients, formulations, and delivery systems for nutraceutical products. Nutraceutical CDMOs collaborate with nutraceutical companies to translate these innovations into market-ready products. R&D advancements also result in a deeper understanding of the health benefits and mechanisms of action of various nutrients and bioactive compounds. Nutraceutical CDMOs facilitate the integration of scientific research into product development, enabling companies to create evidence-based nutraceuticals that are clinically validated and substantiated. These advancements allow for a better understanding of specific health concerns and conditions that nutraceuticals can address, leading to the development of targeted health solutions. Additionally, R&D enhances knowledge of individual nutritional needs based on genetics, lifestyle, and health status, enabling the creation of personalized nutrition solutions.

Key Market Challenges

  • 1. Quality Control and Assurance: Quality control and assurance pose significant challenges to the Global Nutraceutical CDMO market due to the complexity and critical nature of ensuring consistent product quality and safety. Nutraceutical products are subject to regulatory standards that ensure their safety, efficacy, and accurate labeling. Compliance with diverse and evolving regulations in different regions can be complex and time-consuming. Nutraceutical CDMOs must stay up-to-date with changing regulations and adapt their processes accordingly. Ensuring consistent quality and potency across batches is challenging, particularly for complex formulations containing multiple active ingredients. Variability in ingredient characteristics, such as natural ingredients susceptible to seasonal variations, can complicate the process. Nutraceutical CDMOs must carefully select suppliers and establish stringent quality standards to minimize variability.
  • 2. Ingredient Sourcing and Supply Chain Disruptions: Ingredient sourcing and supply chain disruptions can present significant challenges to the Global Nutraceutical CDMO market. The reliability and consistency of ingredient suppliers can vary, affecting the quality and availability of essential components for nutraceutical formulations. Many nutraceutical ingredients are derived from natural sources and may be subject to seasonal variations in availability and quality, impacting consistent product formulations. Geopolitical factors, trade restrictions, and natural disasters can disrupt the supply chain and impact ingredient availability. Ensuring the quality and authenticity of sourced ingredients is crucial, requiring rigorous testing and verification processes.
  • 3. Environmental Sustainability: Environmental sustainability poses a significant challenge to the Global Nutraceutical CDMO market as the industry seeks to balance business growth with responsible environmental practices. Nutraceutical ingredients often have ecological impacts, such as deforestation and habitat destruction, and may threaten local ecosystems and biodiversity. The industry also generates waste, including packaging materials and byproducts. Reducing environmental impact through sustainable sourcing practices, responsible waste management, and eco-friendly packaging alternatives is essential. Additionally, energy consumption and greenhouse gas emissions from manufacturing processes must be addressed through energy-efficient technologies and renewable energy sources.

Key Market Trends

  • 1. Rise of Personalized Nutrition: Personalized nutrition is a significant trend in the Global Nutraceutical CDMO market, influencing how nutraceutical products are developed, formulated, and manufactured. This trend involves tailoring dietary and supplement recommendations to an individual's unique health needs, genetic makeup, lifestyle, and preferences. Nutraceutical CDMOs play a critical role in developing customized formulations that align with the specific requirements of each consumer. This trend requires CDMOs to possess the expertise to create diverse and flexible formulations that can be adjusted based on individual factors. Personalized nutrition relies on comprehensive health assessments, biomarker analysis, and genetic testing to determine an individual's nutritional needs, and CDMOs may collaborate with testing laboratories and healthcare professionals to incorporate these data into the formulation process.
  • 2. Dosage Form Dominance: In 2022, the tablets and capsules segment dominated the Nutraceuticals CDMO market and is expected to continue expanding. Tablets and capsules are popular dosage forms due to their convenience, ease of consumption, and precise dosing capabilities. They offer stability and protection for enclosed ingredients, safeguarding against environmental factors and contributing to longer shelf life. This segment is projected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030.
  • 3. Manufacturing and Packaging Services: Manufacturing and packaging services are pivotal in the Nutraceuticals CDMO market. Manufacturing services encompass the production of nutraceutical products, while packaging services involve design, labeling, and packaging for retail or distribution. Effective packaging is crucial for product differentiation, consumer communication, and regulatory compliance.
  • 4. Mid-Size CDMOs: Mid-size nutraceutical CDMOs are agile and responsive, offering personalized services and building strong client relationships. They often specialize exclusively in the nutraceutical industry, enabling deep expertise in formulation, manufacturing, regulatory compliance, and market trends. Mid-size CDMOs are known for innovation and adaptability, quickly responding to market shifts and introducing

unique nutraceutical products.

  • 5. North America Dominance: North America, particularly the United States, leads the Global Nutraceuticals CDMO Market due to a mature market, strong consumer acceptance of dietary supplements, and well-established regulatory frameworks. North American consumers' increasing focus on health and wellness drives the demand for nutraceutical products, leading to a greater need for CDMO services.

Key Market Players

  • Catalent Inc.
  • Lonza Group AG
  • NUTRASCIENCE LABS Inc
  • Robinson Pharma, Inc.
  • Health Wright Products, Inc.
  • Innovations in Nutrition + Wellness
  • INPHARMA S.p.A.
  • Aenova Group
  • NutraPakUSA
  • SFI Health Pty Ltd.

Report Scope:

In this report, the Global Nutraceuticals CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nutraceuticals CDMO Market, By Dosage Form:

  • Tablets & Capsules
  • Powder
  • Softgel
  • Others

Nutraceuticals CDMO Market, By Service:

  • Product Formulation and Development
  • Manufacturing and Packaging
  • Research & Development (R&D)
  • Regulatory Compliance
  • Others

Nutraceuticals CDMO Market, By Company Size:

  • Small Companies
  • Mid-Sized Companies
  • Large Companies

Global Nutraceuticals CDMO Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Nutraceuticals CDMO Market.

Available Customizations:

  • Global Nutraceuticals CDMO Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nutraceuticals CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Dosage Form (Tablets & Capsules, Powder, Softgel, Others)
    • 5.2.2. By Service (Product Formulation and Development, Manufacturing and Packaging, Research & Development (R&D), Regulatory Compliance, Others)
    • 5.2.3. By Company Size (Small Companies, Mid-Sized Companies, Large Companies)
    • 5.2.4. By Company (2022)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Nutraceuticals CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Dosage Form
    • 6.2.2. By Service
    • 6.2.3. By Company Size
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Nutraceuticals CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value Service
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Dosage Form
        • 6.3.1.2.2. By Service
        • 6.3.1.2.3. By Company Size
    • 6.3.2. Mexico Nutraceuticals CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value Service
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Dosage Form
        • 6.3.2.2.2. By Service
        • 6.3.2.2.3. By Company Size
    • 6.3.3. Canada Nutraceuticals CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value Service
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Dosage Form
        • 6.3.3.2.2. By Service
        • 6.3.3.2.3. By Company Size

7. Europe Nutraceuticals CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Dosage Form
    • 7.2.2. By Service
    • 7.2.3. By Company Size
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Nutraceuticals CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value Service
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Dosage Form
        • 7.3.1.2.2. By Service
        • 7.3.1.2.3. By Company Size
    • 7.3.2. Germany Nutraceuticals CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value Service
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Dosage Form
        • 7.3.2.2.2. By Service
        • 7.3.2.2.3. By Company Size
    • 7.3.3. United Kingdom Nutraceuticals CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value Service
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Dosage Form
        • 7.3.3.2.2. By Service
        • 7.3.3.2.3. By Company Size
    • 7.3.4. Italy Nutraceuticals CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value Service
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Dosage Form
        • 7.3.4.2.2. By Service
        • 7.3.4.2.3. By Company Size
    • 7.3.5. Spain Nutraceuticals CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value Service
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Dosage Form
        • 7.3.5.2.2. By Service
        • 7.3.5.2.3. By Company Size

8. Asia-Pacific Nutraceuticals CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Dosage Form
    • 8.2.2. By Service
    • 8.2.3. By Company Size
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Nutraceuticals CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value Service
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Dosage Form
        • 8.3.1.2.2. By Service
        • 8.3.1.2.3. By Company Size
    • 8.3.2. India Nutraceuticals CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value Service
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Dosage Form
        • 8.3.2.2.2. By Service
        • 8.3.2.2.3. By Company Size
    • 8.3.3. South Korea Nutraceuticals CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value Service
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Dosage Form
        • 8.3.3.2.2. By Service
        • 8.3.3.2.3. By Company Size
    • 8.3.4. Japan Nutraceuticals CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value Service
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Dosage Form
        • 8.3.4.2.2. By Service
        • 8.3.4.2.3. By Company Size
    • 8.3.5. Australia Nutraceuticals CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value Service
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Dosage Form
        • 8.3.5.2.2. By Service
        • 8.3.5.2.3. By Company Size

9. South America Nutraceuticals CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Dosage Form
    • 9.2.2. By Service
    • 9.2.3. By Company Size
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Nutraceuticals CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value Service
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Dosage Form
        • 9.3.1.2.2. By Service
        • 9.3.1.2.3. By Company Size
    • 9.3.2. Argentina Nutraceuticals CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value Service
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Dosage Form
        • 9.3.2.2.2. By Service
        • 9.3.2.2.3. By Company Size
    • 9.3.3. Colombia Nutraceuticals CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value Service
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Dosage Form
        • 9.3.3.2.2. By Service
        • 9.3.3.2.3. By Company Size

10. Middle East and Africa Nutraceuticals CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Dosage Form
    • 10.2.2. By Service
    • 10.2.3. By Company Size
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Nutraceuticals CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value Service
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Dosage Form
        • 10.3.1.2.2. By Service
        • 10.3.1.2.3. By Company Size
    • 10.3.2. Saudi Arabia Nutraceuticals CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value Service
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Dosage Form
        • 10.3.2.2.2. By Service
        • 10.3.2.2.3. By Company Size
    • 10.3.3. UAE Nutraceuticals CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value Service
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Dosage Form
        • 10.3.3.2.2. By Service
        • 10.3.3.2.3. By Company Size

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Catalent Inc.
    • 15.6.2. Lonza Group AG
    • 15.6.3. NUTRASCIENCE LABS Inc
    • 15.6.4. Robinson Pharma, Inc.
    • 15.6.5. Health Wright Products, Inc.
    • 15.6.6. Innovations in Nutrition + Wellness
    • 15.6.7. INPHARMA S.p.A.
    • 15.6.8. Aenova Group
    • 15.6.9. NutraPakUSA
    • 15.6.10. SFI Health Pty Ltd.

16. Strategic Recommendations